Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses
Although the advent of enzyme replacement therapy (ERT) for mucopolysaccharidoses (MPS) has paved the way for the treatment for these hereditary disorders, the blood brain barrier (BBB) has prevented patients with MPS involving the central nervous system (CNS) from benefitting from ERT. Therefore, f...
Main Authors: | Yuji Sato, Torayuki Okuyama |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/2/400 |
Similar Items
-
Identification and in vivo characterization of a brain-penetrating nanobody
by: Y Wouters, et al.
Published: (2020-10-01) -
An Affibody Molecule Is Actively Transported into the Cerebrospinal Fluid via Binding to the Transferrin Receptor
by: Sebastian W. Meister, et al.
Published: (2020-04-01) -
Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations
by: Rossella Parini, et al.
Published: (2020-04-01) -
Mucopolysaccharidoses in northern Brazil: Targeted mutation screening and urinary glycosaminoglycan excretion in patients undergoing enzyme replacement therapy
by: Gustavo M. Viana, et al.
Published: (2011-01-01) -
Integrin α2β1-targeting ferritin nanocarrier traverses the blood–brain barrier for effective glioma chemotherapy
by: Chiun-Wei Huang, et al.
Published: (2021-06-01)